SR One Capital Management

https://www.srone.com

SR One is a transatlantic biotechnology venture capital firm, headquartered in the San Francisco Bay Area, that collaborates with entrepreneurs and investment partners in an effort to build elite biotechnology companies. The Company’s mission is to translate innovative technologies and scientific discoveries into next-generation medicines with the potential to benefit patients with significant unmet medical needs. SR One leadership has worked together to build and invest in biotechnology companies for more than a decade. Working alongside the investment team, SR One’s venture partners bring deep operational experience to help company creation initiatives and support portfolio companies with financing and corporate strategies. Since the spin out from GSK in 2020, SR One has raised over $1 billion and founded and/or invested in over 20 companies. SR One has offces in Redwood City, CA, and Philadelphia, PA, in the US and London in the UK. *

	Start	2020-11-19 splitoff
	Group	SR One (Group)
	Predecessor	SR One Ltd. [old, GSK sub until 2020]
	Industry	venture capital
	Industry 2	pharmaceutical
	Person	George, Simeon (GSK 201504 SR One)
	Person 2	Novak, Rodger (CRISPR Therapeutics 201712– Board Chairman 2013–201711 CEO + Co-Founder before Sanofi + Nabriva GmbH)

	Street	985 Old Eagle School Road Suite 511
	City	19087 Wayne, PA
		Address record changed: 2021-02-12

Basic data	Employees	n. a.

		* Document for »About Section«: SR One Capital Management. (3/27/23). "Press Release: SR One Closes Second Venture Fund at $600M". Redwood City, CA & London.

		Record changed: 2025-01-11